QURE - uniQure NV Stock Price, Fair Value and News

4.90USD+0.02 (+0.41%)Market Closed

Market Summary

USD4.90+0.02

Market Closed

0.41%

QURE Stock Price

View Fullscreen

QURE RSI Chart

QURE Valuation

Market Cap

237.9M

Price/Earnings (Trailing)

-0.8

Price/Sales (Trailing)

12.52

EV/EBITDA

-0.41

Price/Free Cashflow

-1.76

QURE Price/Sales (Trailing)

QURE Profitability

EBT Margin

-1542.31%

Return on Equity

-202.29%

Return on Assets

-38.55%

Free Cashflow Yield

-56.9%

QURE Fundamentals

QURE Revenue

Revenue (TTM)

19.0M

Rev. Growth (Yr)

59.34%

Rev. Growth (Qtr)

26.85%

QURE Earnings

Earnings (TTM)

-296.9M

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

10.37%

Breaking Down QURE Revenue

Last 7 days

1.7%

Last 30 days

2.5%

Last 90 days

-7.4%

Trailing 12 Months

-77.4%

How does QURE drawdown profile look like?

QURE Financial Health

Current Ratio

9.39

Debt/Equity

0.7

Debt/Cashflow

-1.26

QURE Investor Care

Shares Dilution (1Y)

2.03%

Diluted EPS (TTM)

-6.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.0M	0	0	0
2023	108.3M	110.1M	111.9M	15.8M
2022	419.6M	315.2M	210.9M	106.5M
2021	159.1M	280.8M	402.4M	524.0M
2020	14.8M	22.4M	30.0M	37.5M
2019	8.9M	8.4M	6.3M	7.3M
2018	13.3M	11.4M	12.3M	11.3M
2017	24.1M	24.6M	19.7M	13.1M
2016	14.2M	17.8M	21.5M	25.1M
2015	0	0	0	10.6M
2014	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of uniQure NV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	potts jeannette	acquired	-	-	49,500	chief legal officer
Mar 01, 2024	caloz pierre	acquired	-	-	33,000	chief operating officer
Mar 01, 2024	kapusta matthew c	acquired	-	-	150,000	ceo, managing director
Mar 01, 2024	klemt christian	acquired	-	-	49,500	chief financial officer
Mar 01, 2024	abi-saab walid	acquired	-	-	49,500	chief medical officer
Feb 26, 2024	caloz pierre	sold	-61,173	6.47	-9,455	chief operating officer
Feb 26, 2024	klemt christian	sold	-101,480	6.38	-15,906	chief financial officer
Feb 26, 2024	kapusta matthew c	sold	-177,190	6.35	-27,904	ceo, managing director
Sep 18, 2023	dolmetsch ricardo	sold	-43,573	7.46	-5,841	president, r&d
Jul 10, 2023	caloz pierre	sold	-171,729	11.36	-15,117	chief operating officer

Which funds bought or sold QURE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	Financial Gravity Asset Management, Inc.	added	276	178	251	-%
May 13, 2024	ENVESTNET ASSET MANAGEMENT INC	sold off	-100	-152,894	-	-%
May 13, 2024	FOX RUN MANAGEMENT, L.L.C.	sold off	-100	-135,251	-	-%
May 13, 2024	BANK OF MONTREAL /CAN/	added	48.62	24,210	175,284	-%
May 13, 2024	HARBOR CAPITAL ADVISORS, INC.	added	12.9	-28,078	181,000	0.02%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	reduced	-6.84	-510,000	1,281,000	-%
May 13, 2024	Worth Venture Partners, LLC	new	-	178,360	178,360	1.19%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	4.2	-648,453	2,599,670	-%
May 13, 2024	FMR LLC	reduced	-40.95	-180,463	149,791	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	added	126	2,876	7,598	-%

Are Funds Buying or Selling QURE?

Are funds buying QURE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own QURE

No. of Funds

Unveiling uniQure NV's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	6.6%	3,158,027	SC 13G/A
Feb 13, 2024	vestal point capital, lp	8.2%	3,925,000	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	state street corp	7.28%	3,478,872	SC 13G/A
Oct 06, 2023	blackrock inc.	3.6%	1,731,216	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	8.3%	3,887,939	SC 13G/A
Feb 14, 2023	pfm health sciences, lp	4.9%	6	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	3.6%	1,672,830	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 08, 2023	invesco ltd.	0.5%	219,506	SC 13G/A

Recent SEC filings of uniQure NV

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
May 01, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 12, 2024	8-K	Current Report
Apr 12, 2024	PRE 14A	PRE 14A
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to uniQure NV)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

uniQure NV News

Latest updates

uniQure NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	26.9%	8,485,000	6,689,000	1,407,000	2,422,000	5,325,000	102,745,000	51,621,000	497,000	29,094,000	57,691,000	1,989,000	12,688,000	23,387,000	34,086,000	1,789,000	1,535,000	2,080,000	2,625,000	1,046,000	2,474,000	1,136,000
Costs and Expenses	-7.4%	63,855,000	68,942,000	84,480,000	68,569,000	81,092,000	78,235,000	62,253,000	59,515,000	55,990,000	58,104,000	48,455,000	73,224,000	45,031,000	42,892,000	47,091,000	39,912,000	35,085,000	35,170,000	32,483,000	32,024,000	28,604,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,604,000
S&GA Expenses	-20.3%	13,937,000	17,488,000	18,074,000	21,181,000	17,848,000	18,257,000	13,324,000	12,491,000	10,987,000	14,280,000	12,023,000	17,299,000	12,375,000	11,208,000	10,789,000	11,511,000	9,072,000	8,678,000	8,929,000	7,870,000	8,067,000
R&D Expenses	-4.5%	40,692,000	42,619,000	65,400,000	46,036,000	60,809,000	58,328,000	48,068,000	46,192,000	45,003,000	42,026,000	36,432,000	32,747,000	32,656,000	31,684,000	36,302,000	28,401,000	26,013,000	26,492,000	23,554,000	24,154,000	20,537,000
EBITDA Margin	-Infinity%	-12.03	-	-1.70	-1.47	-1.27	-1.01	-0.51	-0.31	0.82	0.66	0.80	1.09	-0.88	-	-	-	-	-	-	-	-
Interest Expenses	2.5%	16,097,000	15,711,000	15,444,000	6,840,000	3,562,000	3,425,500	3,069,000	2,694,000	2,515,000	2,097,000	1,924,000	1,902,000	1,551,000	938,000	942,000	970,000	975,000	956,000	960,000	937,000	957,000
Income Taxes	-78.4%	656,000	3,034,000	-69,000	163,000	-1,207,000	-207,000	-329,000	-318,000	-616,000	-343,000	89,000	3,258,000	213,000	-16,419,000	-	-	-	-	-	-	-
Earnings Before Taxes	7.4%	-64,962,000	-70,172,000	-89,640,000	-68,311,000	-78,434,000	6,600,000	-48,186,000	-39,379,000	-47,294,000	7,865,000	-36,442,000	402,726,000	-41,343,000	-17,118,000	-53,775,000	-42,551,000	-27,999,000	-41,426,000	-23,604,000	-31,399,000	-27,772,000
EBT Margin	20.3%	-15.42	-19.35	-2.05	-1.71	-1.47	-1.20	-0.60	-0.37	0.78	0.64	0.77	1.03	-	-	-	-	-	-	-	-	-
Net Income	10.4%	-65,618,000	-73,206,000	-89,571,000	-68,474,000	-77,227,000	6,807,000	-47,857,000	-39,061,000	-46,678,000	8,208,000	-36,531,000	399,468,000	-41,556,000	-699,000	-53,775,000	-42,551,000	-27,999,000	-41,426,000	-23,604,000	-31,399,000	-27,772,000
Net Income Margin	19.8%	-15.62	-19.47	-2.04	-1.70	-1.45	-1.19	-0.59	-0.36	0.77	0.63	0.80	1.08	-	-	-	-	-	-	-	-	-
Free Cashflow	-22.0%	-62,919,000	-51,579,000	37,211,000	-58,071,000	-80,644,000	-59,746,000	-52,976,000	-20,257,000	-29,769,000	-50,643,000	-47,851,000	414,164,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.4%	770	832	872	943	631	705	638	701	757	809	775	784	364	340	351	385	414	449	472	253	269
Current Assets	-8.6%	596	652	694	757	443	477	465	523	578	628	594	694	282	259	287	320	350	384	408	189	213
Cash Equivalents	2.0%	246	241	229	514	154	228	440	501	525	556	578	677	261	248	279	314	342	381	403	184	209
Inventory	-36.2%	8.00	12.00	16.00	10.00	7.00	7.00	4.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.3%	45.00	47.00	46.00	49.00	50.00	51.00	48.00	46.00	45.00	44.00	41.00	38.00	34.00	32.00	30.00	29.00	28.00	29.00	28.00	28.00	28.00
Goodwill	-2.2%	26.00	26.00	25.00	26.00	26.00	26.00	23.00	25.00	27.00	28.00	28.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	0.00
Liabilities	-0.1%	623	624	603	589	218	229	217	215	211	213	184	151	135	96.00	123	120	119	126	121	121	112
Current Liabilities	-13.8%	63.00	74.00	69.00	68.00	66.00	76.00	64.00	48.00	45.00	37.00	42.00	46.00	32.00	27.00	33.00	30.00	27.00	32.00	28.00	23.00	22.00
Long Term Debt	0.4%	102	102	101	101	103	103	102	102	101	101	71.00	71.00	70.00	36.00	35.00	35.00	36.00	36.00	36.00	36.00	36.00
LT Debt, Non Current	-100.0%	-	102	101	101	103	103	102	102	101	101	71.00	71.00	70.00	36.00	35.00	35.00	36.00	36.00	36.00	36.00	36.00
Shareholder's Equity	-29.3%	147	208	269	353	413	476	421	486	546	596	591	634	229	244	228	266	295	323	350	132	157
Retained Earnings	-7.4%	-956	-890	-817	-727	-659	-581	-588	-540	-501	-455	-463	-426	-826	-784	-784	-730	-687	-659	-618	-594	-563
Additional Paid-In Capital	0.6%	1,156	1,149	1,142	1,131	1,122	1,113	1,100	1,092	1,084	1,077	1,069	1,062	1,050	1,016	1,007	1,000	992	987	981	733	728
Accumulated Depreciation	3.8%	58.00	56.00	52.00	49.00	47.00	44.00	41.00	39.00	39.00	37.00	36.00	37.00	36.00	35.00	33.00	31.00	30.00	29.00	27.00	26.00	-
Shares Outstanding	1.4%	48.00	48.00	48.00	48.00	48.00	47.00	47.00	47.00	47.00	46.00	46.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	547	-	-	-	870	-	-	-	1,418	-	-	-	2,003	-	-	-	2,957	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-22.3%	-60,575	-49,541	38,911	-56,997	-78,302	-54,680	-48,991	-15,678	-25,711	-47,090	-40,157	416,479	-41,273	-37,175	-34,709	-29,991	-32,953	-26,007	-22,020	-24,219	-26,438
Share Based Compensation	2.1%	7,191	7,041	11,097	8,894	8,061	11,914	7,608	7,814	6,868	6,888	5,955	7,031	5,761	5,381	6,372	5,723	4,355	4,771	3,876	4,592	4,294
Cashflow From Investing	7.4%	63,985	59,562	-314,066	45,830	2,988	-168,212	-5,063	-4,579	-4,880	-3,553	-57,643	-2,315	-3,876	-2,695	-2,183	-1,716	-2,890	-1,963	-2,256	-1,198	-1,230
Cashflow From Financing	-100.0%	-	46.00	-7,593	370,137	131	601	301	58.00	485	29,894	-164	2,510	62,618	3,756	139	2,539	1,010	1,310	244,290	543	2,678

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

QURE Income Statement

2024-03-31

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 8,485	$ 5,325
Operating expenses:
Cost of license revenues	(150)
Cost of contract manufacturing revenues	(9,076)	(2,435)
Research and development expenses	(40,692)	(60,809)
Selling, general and administrative expenses	(13,937)	(17,848)
Total operating expenses	(63,855)	(81,092)
Other income	1,376	1,811
Other expense	(234)	(216)
Loss from operations	(54,228)	(74,172)
Interest income	6,508	1,669
Interest expense	(16,097)	(3,562)
Foreign currency losses, net	(1,145)	(2,369)
Loss before income tax (expense) / benefit	(64,962)	(78,434)
Income tax (expense) / benefit	(656)	1,207
Net loss	(65,618)	(77,227)
Other comprehensive (loss) / income:
Foreign currency translation (loss) / gains, net	(2,524)	5,797
Defined benefit pension gain, net of taxes	35
Total comprehensive loss	$ (68,107)	$ (71,430)
Earnings per ordinary share - basic
Basic net (loss) / income per ordinary share	$ (1.36)	$ (1.63)
Earnings per ordinary share - diluted
Diluted net (loss) / income per ordinary share	$ (1.36)	$ (1.63)
Weighted average shares - basic	48,384,510	47,436,335
Weighted average shares - diluted	48,384,510	47,436,335
License revenues
Total revenues	$ 1,202	$ 0
Contract manufacturing revenues
Total revenues	3,990	4,937
Collaboration revenues
Total revenues	$ 3,293	$ 388

QURE Balance Sheet

2024-03-31

UNAUDITED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 243,062	$ 241,360
Current investment securities	312,621	376,532
Accounts receivable	10,717	4,193
Inventories, net	7,672	12,024
Prepaid expenses	18,839	15,089
Other current assets and receivables	3,092	2,655
Total current assets	596,003	651,853
Non-current assets
Property, plant and equipment, net of accumulated depreciation of $57.8 million as of March 31, 2024 and $55.7 million as of December 31, 2023	44,554	46,548
Operating lease right-of-use assets	27,695	28,789
Intangible assets, net, including in-process research and development asset of $57.8 million as of March 31, 2024 and $59.1 million as of December 31, 2023	59,111	60,481
Goodwill	25,795	26,379
Deferred tax assets, net	11,594	12,276
Other non-current assets	5,298	5,363
Total non-current assets	174,047	179,836
Total assets	770,050	831,689
Current liabilities
Accounts payable	5,231	6,586
Accrued expenses and other current liabilities	22,658	30,534
Current portion of contingent consideration	27,587	28,211
Current portion of operating lease liabilities	7,997	8,344
Total current liabilities	63,473	73,675
Non-current liabilities
Long-term debt	102,120	101,749
Liability from royalty financing agreement	405,398	394,241
Operating lease liabilities, net of current portion	26,983	28,316
Contingent consideration, net of current portion	14,625	14,795
Deferred tax liability, net	7,376	7,543
Other non-current liabilities	3,321	3,700
Total non-current liabilities	559,823	550,344
Total liabilities	623,296	624,019
Commitments and contingencies
Shareholders' equity
Ordinary shares, €0.05 par value: 80,000,000 shares authorized as of March 31, 2024 and December 31, 2023 and 48,492,357 and 47,833,830 ordinary shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2,919	2,883
Additional paid-in-capital	1,155,904	1,148,749
Accumulated other comprehensive loss	(56,042)	(53,553)
Accumulated deficit	(956,027)	(890,409)
Total shareholders' equity	146,754	207,670
Total liabilities and shareholders' equity	$ 770,050	$ 831,689

About uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

CEO	Mr. Matthew Craig Kapusta
WEBSITE	uniqure.com
INDUSTRY	Biotechnology
EMPLOYEES	501

uniQure NV Frequently Asked Questions

What is the ticker symbol for uniQure NV? What does QURE stand for in stocks?

QURE is the stock ticker symbol of uniQure NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of uniQure NV (QURE)?

As of Tue May 14 2024, market cap of uniQure NV is 237.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of QURE stock?

You can check QURE's fair value in chart for subscribers.

What is the fair value of QURE stock?

You can check QURE's fair value in chart for subscribers. The fair value of uniQure NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of uniQure NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for QURE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is uniQure NV a good stock to buy?

The fair value guage provides a quick view whether QURE is over valued or under valued. Whether uniQure NV is cheap or expensive depends on the assumptions which impact uniQure NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QURE.

What is uniQure NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, QURE's PE ratio (Price to Earnings) is -0.8 and Price to Sales (PS) ratio is 12.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. QURE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on uniQure NV's stock?

In the past 10 years, uniQure NV has provided -0.065 (multiply by 100 for percentage) rate of return.